Home Cart Sign in  
Chemical Structure| 1338247-35-0 Chemical Structure| 1338247-35-0

Structure of BMS-5
CAS No.: 1338247-35-0

Chemical Structure| 1338247-35-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-5 is a highly selective and potent inhibitor of both LIMK 1 and 2 with IC50 values of 7 and 8 nM, respectively.

Synonyms: LIMKi 3; LIM Kinase Inhibitor I

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-5

CAS No. :1338247-35-0
Formula : C17H14Cl2F2N4OS
M.W : 431.29
SMILES Code : CC(C)C(NC1=NC=C(C2=CC(C(F)F)=NN2C3=C(Cl)C=CC=C3Cl)S1)=O
Synonyms :
LIMKi 3; LIM Kinase Inhibitor I
MDL No. :MFCD17019327
InChI Key :IVUGBSGLHRJSSP-UHFFFAOYSA-N
Pubchem ID :56965901

Safety of BMS-5

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Nf2ΔEx2 mouse Schwann cells 5 µM 7 h Treatment with 5 µM BMS-5 resulted in accumulation of Nf2ΔEx2 MSCs in the G2/M phase, increasing the proportion from 20% to 42%. Oncogene. 2014 Jul 3;33(27):3571-82
Nf2ΔEx2 mouse Schwann cells 3.9 µM 24 h BMS-5 reduced Nf2ΔEx2 MSC viability in a dose-dependent manner with an IC50 of 3.9 µM, but did not significantly affect the viability of control Nf2flox2/flox2 MSCs at equivalent concentrations. Oncogene. 2014 Jul 3;33(27):3571-82
Nf2ΔEx2 mouse Schwann cells 2 µM 30 min BMS-5 inhibited cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2ΔEx2 MSCs with an IC50 of ~2 µM. Oncogene. 2014 Jul 3;33(27):3571-82
human neurons derived from sporadic Alzheimer's disease patients 1 μM from day 7 to the end To investigate the effect of LIMK1 inhibition on neuronal morphology, results showed no further worsening of neurite length Alzheimers Res Ther. 2024 Dec 19;16(1):267
human neurons derived from healthy subjects 1 μM from day 7 to the end To investigate the effect of LIMK1 inhibition on neuronal morphology, results showed reduced neurite length Alzheimers Res Ther. 2024 Dec 19;16(1):267
rod photoreceptor cells 10 μM 7 h Stabilizes actin filaments, preventing their depolymerization during axon retraction Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2274-2285
rod photoreceptor cells 10 μM 15 min Inhibits LIMK activity, reduces the production of actin barbed ends, thereby decreasing actin filament severing in the axonal region of rod photoreceptors Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2274-2285
rod photoreceptor cells 1-30 μM 7 h Inhibition of LIMK significantly reduced axonal retraction in rod photoreceptor cells. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7847-58
mouse embryo cells 200 μM and 400 μM Inhibition of LIMK1/2 activity caused failure of early embryo cleavage and defects in blastocyst formation Cell Cycle. 2018;17(11):1381-1389

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.59mL

2.32mL

1.16mL

23.19mL

4.64mL

2.32mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories